• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acceptable changes in quality attributes of glycosylated biopharmaceuticals.

作者信息

Schiestl Martin, Stangler Thomas, Torella Claudia, Cepeljnik Tadej, Toll Hansjörg, Grau Roger

出版信息

Nat Biotechnol. 2011 Apr;29(4):310-2. doi: 10.1038/nbt.1839.

DOI:10.1038/nbt.1839
PMID:21478841
Abstract
摘要

相似文献

1
Acceptable changes in quality attributes of glycosylated biopharmaceuticals.糖基化生物制药质量属性的可接受变化
Nat Biotechnol. 2011 Apr;29(4):310-2. doi: 10.1038/nbt.1839.
2
An industry perspective on plasma-derived products.行业对血浆衍生产品的看法。
Dev Biol (Basel). 2004;118:31-5.
3
Current and future approaches to ensure the viral safety of biopharmaceuticals.确保生物制药病毒安全性的当前及未来方法。
Dev Biol (Basel). 2004;118:17-29.
4
Biosimilars: policy, clinical, and regulatory considerations.生物类似药：政策、临床及监管考量
Am J Health Syst Pharm. 2008 Jul 15;65(14 Suppl 6):S2-8. doi: 10.2146/ajhp080210.
5
Biosimilars: evidential standards for health technology assessment.生物类似药：卫生技术评估的证据标准
Clin Pharmacol Ther. 2010 Mar;87(3):257-61. doi: 10.1038/clpt.2009.112.
6
Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP.在接受（±R）CHOP方案治疗的非霍奇金淋巴瘤和化疗所致贫血患者中使用阿法达贝泊汀。
Hematology. 2013 Jan;18(1):26-9. doi: 10.1179/1607845412Y.0000000033. Epub 2012 Sep 12.
7
Darbepoetin alfa: a novel erythropoiesis-stimulating protein.达贝泊汀α：一种新型促红细胞生成蛋白。
Drugs Today (Barc). 2003 Jul;39(7):477-95. doi: 10.1358/dot.2003.39.7.799441.
8
Comparative Assessment of the Effect of Hyper-glycosylation on the Pattern and Kinetics of Degradation of Darbepoetin Alfa using a Stability-Indicating Orthogonal Testing Protocol.使用稳定性指示正交试验方案对高糖基化对达贝泊汀α降解模式和动力学的影响进行比较评估。
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 1;1072:405-414. doi: 10.1016/j.jchromb.2017.10.057. Epub 2017 Nov 4.
9
Current legal, regulatory, and scientific implications of biosimilars. Introduction.生物类似药当前的法律、监管及科学影响。引言。
Am J Health Syst Pharm. 2008 Jul 15;65(14 Suppl 6):S1. doi: 10.2146/ajhp080209.
10
Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations.优化促红细胞生成剂的使用——药代动力学和药效学考量
Nephrol Dial Transplant. 2002;17 Suppl 5:66-70. doi: 10.1093/ndt/17.suppl_5.66.

引用本文的文献

1
Comprehensive Physico-chemical and Functional Similarity Assessment Study of RGB-14-P and RGB-14-X Drug Products as Proposed Biosimilars to Denosumab Reference Products.RGB-14-P和RGB-14-X药品作为地诺单抗参比制剂的拟生物类似药的综合理化及功能相似性评估研究
BioDrugs. 2025 Sep;39(5):697-724. doi: 10.1007/s40259-025-00738-w. Epub 2025 Aug 6.
2
Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies.向美国食品药品监督管理局提交的关于免除对比疗效研究的科学依据及政策建议。
Pharmaceuticals (Basel). 2025 May 23;18(6):779. doi: 10.3390/ph18060779.
3

本文引用的文献

1
Understanding and circumventing resistance to anticancer monoclonal antibodies.了解并克服对抗癌单克隆抗体的耐药性。
MAbs. 2009 May-Jun;1(3):222-9. doi: 10.4161/mabs.1.3.8292. Epub 2009 May 24.
2
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.肿瘤坏死因子拮抗剂的作用机制：全面综述
Pharmacol Ther. 2008 Feb;117(2):244-79. doi: 10.1016/j.pharmthera.2007.10.001. Epub 2007 Oct 26.
3
Mechanisms of killing by anti-CD20 monoclonal antibodies.抗CD20单克隆抗体的杀伤机制。
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase.
日本批准的生物类似单克隆抗体及其参照产品的特性分析，以揭示批准后阶段的质量特征。
BioDrugs. 2025 May 7. doi: 10.1007/s40259-025-00722-4.
4
PET Imaging Expedites Detection of Aberration in the Humanization of an Annexin A1 Targeting Antibody.正电子发射断层扫描（PET）成像加速了膜联蛋白A1靶向抗体人源化过程中异常情况的检测。
Pharmaceuticals (Basel). 2025 Feb 21;18(3):295. doi: 10.3390/ph18030295.
5
"Small is beautiful" - Examining reliable determination of low-abundant therapeutic antibody glycovariants.“小即美”——探讨低丰度治疗性抗体糖变体的可靠测定方法。
J Pharm Anal. 2024 Oct;14(10):100982. doi: 10.1016/j.jpha.2024.100982. Epub 2024 Apr 26.
6
Soft-sensor model development for CHO growth/production, intracellular metabolite, and glycan predictions.用于预测中国仓鼠卵巢细胞生长/生产、细胞内代谢物和聚糖的软传感器模型开发。
Front Mol Biosci. 2024 Oct 22;11:1441885. doi: 10.3389/fmolb.2024.1441885. eCollection 2024.
7
Pregnancy-related changes in the canine serum N-glycosylation pattern studied by Rapifluor HILIC-UPLC-FLR-MS.基于 Rapifluor HILIC-UPLC-FLR-MS 研究犬血清 N-糖基化模式的妊娠相关变化。
Sci Rep. 2024 Sep 6;14(1):20861. doi: 10.1038/s41598-024-71352-z.
8
In situ production and secretion of proteins endow therapeutic benefit against psoriasiform dermatitis and melanoma.原位产生和分泌蛋白质赋予了治疗银屑病样皮炎和黑色素瘤的益处。
Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2313009120. doi: 10.1073/pnas.2313009120. Epub 2023 Dec 18.
9
A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.对美国食品药品监督管理局基于组学的药效学生物标志物以确立生物相似性的批判性分析。
Pharmaceuticals (Basel). 2023 Nov 2;16(11):1556. doi: 10.3390/ph16111556.
10
Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?哺乳动物细胞培养中的温度上调：生物类似单克隆抗体的合适策略？
Bioengineering (Basel). 2023 Sep 30;10(10):1149. doi: 10.3390/bioengineering10101149.
Mol Immunol. 2007 Sep;44(16):3823-37. doi: 10.1016/j.molimm.2007.06.151.
4
Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.人源化Lewis-Y特异性IgG抗体的赖氨酸剪切分析及其与Fc介导的效应器功能的关系。
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):250-6. doi: 10.1016/j.jchromb.2007.01.024. Epub 2007 Jan 26.
5
Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides.使用模型肽确定单克隆抗体中N端焦谷氨酸变异的起源
Biotechnol Bioeng. 2007 Jun 15;97(3):544-53. doi: 10.1002/bit.21260.
6
Characterizing biological products and assessing comparability following manufacturing changes.表征生物制品并评估生产变更后的可比性。
Nat Biotechnol. 2004 Nov;22(11):1383-91. doi: 10.1038/nbt1030.
7
Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.与重组人促红细胞生成素相比，达比泊汀α具有更长的循环半衰期和更强的体内活性。
Exp Hematol. 2003 Apr;31(4):290-9. doi: 10.1016/s0301-472x(03)00006-7.
8
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.人IgG1 N-连接寡糖上岩藻糖的缺失可改善其与人FcγRIII的结合及抗体依赖性细胞毒性。
J Biol Chem. 2002 Jul 26;277(30):26733-40. doi: 10.1074/jbc.M202069200. Epub 2002 May 1.
9
Development and characterization of novel erythropoiesis stimulating protein (NESP).新型促红细胞生成素（NESP）的研发与特性研究
Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):3-10. doi: 10.1054/bjoc.2001.1746.